Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease

Canadian Journal of Ophthalmology

Volumn 50, Issue 6, 2015, Pages 442-450

  Navajas, Eduardo V ^a   Krema, Hatem ^b   Hammoudi, Dena S ^b   Lipton, Jeffrey H ^c   Simpson, E Rand ^b   Boyd, Shelley ^d   Easterbrook, Michael ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE; ANTIMALARIAL AGENT;

ADULT; AGED; AMSLER CHART; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; COLOR VISION; COLOR VISION TEST; DRUG MEGADOSE; ELECTRORETINOGRAPHY; EYE PHOTOGRAPHY; FEMALE; FOLLOW UP; FUNDUS PHOTOGRAPHY; HUMAN; HUMPHREY PERIMETER; KERATOPATHY; MALE; MIDDLE AGED; MULTIFOCAL ELECTRORETINOGRAPHY; OPHTHALMOLOGY; PERIMETRY; RETINA DISEASE; RETINA MACULOPATHY; RETINAL TOXICITY; RETINOPATHY; SCOTOMA; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; TOXICITY; TREATMENT DURATION; VISUAL ACUITY; VISUAL FIELD; CHEMICALLY INDUCED; CHRONIC DISEASE; COLOR VISION DEFECTS; DRUG EFFECTS; GRAFT VS HOST DISEASE; INCIDENCE; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; RETINA; RETINAL DISEASES;

ADULT; AGED; ANTIMALARIALS; CHRONIC DISEASE; COLOR VISION DEFECTS; ELECTRORETINOGRAPHY; FEMALE; GRAFT VS HOST DISEASE; HUMANS; HYDROXYCHLOROQUINE; INCIDENCE; MALE; MIDDLE AGED; RETINA; RETINAL DISEASES; SCOTOMA; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY; VISUAL FIELD TESTS;

EID: 84951790853     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/j.jcjo.2015.08.003     Document Type: Article

References (40)

1. T. Fong, K. Trinkaus, D. Adkins, and et al. A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation Biol Blood Marrow Transplant 13 2007 1201 1206
2. K. Sperber, H. Quraishi, T. Kalb, A. Panja, V. Stecher, and L. Mayer Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1 alpha) and IL-6 in human monocytes and T cells J Rheumatol 20 1993 803 808
3. A.L. Gilman, K.W. Chan, A. Mogul, and et al. Hydroxychloroquine for the treatment of chronic graft-versus-host disease Biol Blood Marrow Transplant 6 2000 327 334
4. H.N. Bernstein Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy Am J Med 75 1983 25 34
5. M. Easterbrook Ocular effects and safety of antimalarial agents Am J Med 85 1988 23 29
6. R. Tehrani, R.A. Ostrowski, R. Hariman, and W.M. Jay Ocular toxicity of hydroxychloroquine Semin Ophthalmol 23 2008 201 209
7. D.J. Grierson Hydroxychloroquine and visual screening in a rheumatology outpatient clinic Ann Rheum Dis 56 1997 188 190
8. I. Mavrikakis, P.P. Sfikakis, E. Mavrikakis, and et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal Ophthalmology 110 2003 1321 1326
9. R.V. Shearer, and E.L. Dubois Ocular changes induced by long term hydroxychloroquine (Plaquenil) therapy Am J Ophthalmol 64 1967 245 252
10. R.I. Rynes Ophthalmologic safety of long-term hydroxychloroquine sulfate treatment Am J Med 75 1983 35 39
11. M. Johnson, and A. Vine Hydroxychloroquine therapy in massive total doses without retinal toxicity Am J Ophthalmol 104 1987 139 144
12. G.D. Levy, S.J. Munz, J. Paschal, H.B. Cohen, K.J. Pince, and T. Peterson Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice Arthritis Rheum 40 1997 1482 1486
13. C. Wang, P. Fortin, Y. LI, T. Panaritis, M. Gans, and J. Esdaile Discontinuation of antimalarials drugs in systemic lupus erythematomatous J Rheumatol 26 1999 808 815
14. E.M. Adams, D.E. Yocum, and C.L. Bell Hydroxychloroquine in the treatment of rheumatoid arthritis Am J Med 75 1983 321 326
15. C.D. Morsman, S.J. Livesey, I.M. Richards, J.D. Jessop, and P.V. Mills Screening for hydroxychloroquine retinal toxicity: is it necessary? Eye 4 pt 4 1990 572 576
16. L.A. Runge Risk/benefit analysis of hydroxychloroquine sulfate treatment in rheumatoid arthritis Am J Med 75 1983 52 56
17. D. Finbloom, K. Silver, D. Newsome, and R. Gunkel Comparison of hydroxychloroquine and chloroquine and the development of retinal toxicity J Rheumatol 12 1985 692 694
18. M. Mäntyjärvi Hydroxychloroquine treatment and the eye Scand J Rheumatol 14 1985 171 174
19. F. Wolfe, and M.F. Marmor Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus Arthritis Care Res 62 2010 775 784
20. M.F. Marmor, U. Kellner, T.Y.Y. Lai, J.S. Lyons, and W.F. Mieler Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy Ophthalmology 118 2011 415 422
21. H. Khoury, K. Trinkaus, M.J. Zhang, and et al. Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation Biol Blood Marrow Transplant 9 2003 714 721
22. M.F. Marmor, R.E. Carr, M. Easterbrook, A.A. Farjo, and W.F. Mieler Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology Ophthalmology 109 2002 1377 1382
23. M.F. Marmor, and R.B. Melles Disparity between visual fields and optical coherence tomography in hydroxychloroquine retinopathy Ophthalmology 121 2014 1257 1262
24. J.C.S. Yam, and A.K.H. Kwok Ocular toxicity of hydroxychloroquine Hong Kong Med J 12 2006 294 304
25. E. Thomas, R. Storb, R. Clift, and et al. Bone-marrow transplantation (first of two parts) N Engl J Med 292 1975 832 843
26. M. Easterbrook Screening for antimalarial toxicity: current concepts Can J Ophthalmol 37 2002 325 328
27. E.E. Sutter, and D. Tran The field topography of ERG components in man - I. The photopic luminance response Vision Res 32 1992 433 446
28. P.J. Penrose, R.T. Tzekov, E.E. Sutter, and et al. Multifocal electroretinography evaluation for early detection of retinal dysfunction in patients taking hydroxychloroquine Retina 23 2003 503 512
29. H.N. Bernstein Ocular safety of hydroxychloroquine Ann Ophthalmol 23 1991 292 296
30. M. Easterbrook The ocular safety of hydroxychloroquine Semin Arthritis Rheum 23 2 Suppl 1 1993 62S 67SS
31. N.F. Shroyer, R.A. Lewis, and J.R. Lupski Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: is retinal toxicity by chloroquine and hydroxychloroquine related to Stargardt disease? Am J Ophthalmol 131 2001 761 766
32. A. Almony, S. Garg, R.K. Peters, and et al. Threshold Amsler grid as a screening tool for asymptomatic patients on hydroxychloroquine therapy Br J Ophthalmol 89 2005 569 574
33. U. Kellner, A.B. Renner, and H. Tillack Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine Invest Ophthalmol Vis Sci 47 2006 3531 3538
34. T.Y. Lai, W.M. Chan, H. Li, R.Y. Lai, and D.S. Lam Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy Am J Ophthalmol 140 2005 794 807
35. J.S. Lyons, and M.L. Severns Using multifocal ERG ring ratios to detect and follow Plaquenil retinal toxicity: a review: review of mfERG ring ratios in Plaquenil toxicity Doc Ophthalmol 118 2009 29 36
36. J.A. Rodriguez-Padilla, T.R. Hedges, B. Monson, and et al. High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathy Arch Ophthalmol 125 2007 775 780
37. K.E. Stepien, D.P. Han, J. Schell, P. Godara, J. Rha, and J. Carroll Spectral-domain optical coherence tomography and adaptive optics may detect hydroxychloroquine retinal toxicity before symptomatic vision loss Trans Am Ophthalmol Soc 107 2009 28 33
38. S. Kellner, S. Weinitz, and U. Kellner Spectral domain optical coherence tomography detects early stages of chloroquine retinopathy similar to multifocal electroretinography, fundus autofluorescence and near-infrared autofluorescence Br J Ophthalmol 93 2009 1444 1447
39. P. Grutzner Acquired color vision defects secondary to retinal drug toxicity Ophthalmologica 158 suppl 1969 592 604
40. W. Jaeger [Acquired colour-vision-deficiencies caused by side-effects of pharmacotherapy (author's transl)] Klin Monbl Augenheilkd 170 1977 453 460